Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Receivables (2016 - 2024)

vTv Therapeutics' Change in Receivables history spans 10 years, with the latest figure at -$180000.0 for Q4 2024.

  • For Q4 2024, Change in Receivables fell 276.47% year-over-year to -$180000.0; the TTM value through Dec 2024 reached -$40000.0, up 43.66%, while the annual FY2024 figure was -$40000.0, 43.66% up from the prior year.
  • Change in Receivables for Q4 2024 was -$180000.0 at vTv Therapeutics, down from -$64000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $928000.0 in Q3 2021 and bottomed at -$871000.0 in Q4 2021.
  • The 5-year median for Change in Receivables is -$2000.0 (2021), against an average of $4133.3.
  • The largest YoY upside for Change in Receivables was 6528.57% in 2021 against a maximum downside of 704.86% in 2021.
  • A 5-year view of Change in Receivables shows it stood at $144000.0 in 2020, then crashed by 704.86% to -$871000.0 in 2021, then skyrocketed by 113.32% to $116000.0 in 2022, then fell by 12.07% to $102000.0 in 2023, then tumbled by 276.47% to -$180000.0 in 2024.
  • Per Business Quant, the three most recent readings for VTVT's Change in Receivables are -$180000.0 (Q4 2024), -$64000.0 (Q3 2024), and -$675000.0 (Q2 2024).